| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 106 | 2025 | 121 | 38.000 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 40 | 2024 | 143 | 12.900 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 57 | 2025 | 1207 | 10.200 |
Why?
|
| Pyrazoles | 32 | 2025 | 305 | 7.480 |
Why?
|
| Myeloid Differentiation Factor 88 | 38 | 2024 | 85 | 7.330 |
Why?
|
| Pyrimidines | 33 | 2025 | 369 | 7.320 |
Why?
|
| Protein Kinase Inhibitors | 27 | 2025 | 530 | 6.470 |
Why?
|
| Piperidines | 39 | 2025 | 204 | 5.570 |
Why?
|
| Multiple Myeloma | 21 | 2024 | 170 | 5.340 |
Why?
|
| Antineoplastic Agents | 33 | 2025 | 1651 | 5.320 |
Why?
|
| Receptors, CXCR4 | 25 | 2022 | 58 | 5.200 |
Why?
|
| Adenine | 37 | 2025 | 101 | 5.120 |
Why?
|
| Rituximab | 32 | 2024 | 157 | 4.840 |
Why?
|
| Plasmablastic Lymphoma | 8 | 2024 | 8 | 4.480 |
Why?
|
| Lymphoma, B-Cell | 7 | 2024 | 142 | 3.560 |
Why?
|
| Epstein-Barr Virus Infections | 12 | 2024 | 292 | 3.540 |
Why?
|
| Immunoglobulin M | 18 | 2022 | 211 | 3.200 |
Why?
|
| Prognosis | 62 | 2025 | 4607 | 3.080 |
Why?
|
| Lymphoma, AIDS-Related | 7 | 2016 | 39 | 2.800 |
Why?
|
| Aged | 106 | 2025 | 19520 | 2.800 |
Why?
|
| Aged, 80 and over | 59 | 2025 | 6460 | 2.620 |
Why?
|
| Humans | 235 | 2025 | 124020 | 2.580 |
Why?
|
| Mutation | 33 | 2023 | 5798 | 2.400 |
Why?
|
| Middle Aged | 106 | 2025 | 26572 | 2.390 |
Why?
|
| B-Lymphocytes | 10 | 2016 | 532 | 2.350 |
Why?
|
| Doxorubicin | 22 | 2024 | 290 | 2.130 |
Why?
|
| Bortezomib | 9 | 2024 | 73 | 2.040 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 6 | 2023 | 15 | 2.030 |
Why?
|
| Cyclophosphamide | 22 | 2024 | 418 | 2.020 |
Why?
|
| Vincristine | 20 | 2024 | 191 | 2.010 |
Why?
|
| Prednisone | 19 | 2024 | 274 | 2.010 |
Why?
|
| Lymphoma | 8 | 2021 | 322 | 1.980 |
Why?
|
| Hodgkin Disease | 6 | 2016 | 293 | 1.970 |
Why?
|
| Bone Marrow | 12 | 2023 | 324 | 1.960 |
Why?
|
| Survival Rate | 27 | 2025 | 2035 | 1.940 |
Why?
|
| Proteasome Inhibitors | 12 | 2021 | 61 | 1.940 |
Why?
|
| Molecular Targeted Therapy | 9 | 2025 | 353 | 1.930 |
Why?
|
| HIV Infections | 12 | 2023 | 1889 | 1.860 |
Why?
|
| Male | 124 | 2025 | 60919 | 1.840 |
Why?
|
| Lymphoma, Non-Hodgkin | 9 | 2015 | 163 | 1.830 |
Why?
|
| Adult | 83 | 2025 | 29292 | 1.780 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 6 | 2022 | 61 | 1.770 |
Why?
|
| Immunotherapy | 9 | 2025 | 664 | 1.760 |
Why?
|
| Survival Analysis | 27 | 2025 | 1490 | 1.740 |
Why?
|
| Disease Management | 10 | 2024 | 519 | 1.740 |
Why?
|
| Treatment Outcome | 46 | 2025 | 12267 | 1.710 |
Why?
|
| Female | 116 | 2025 | 66198 | 1.610 |
Why?
|
| SEER Program | 10 | 2018 | 202 | 1.570 |
Why?
|
| Neoplasm Proteins | 5 | 2021 | 667 | 1.520 |
Why?
|
| Antigens, CD20 | 7 | 2019 | 37 | 1.480 |
Why?
|
| Herpesvirus 4, Human | 10 | 2024 | 676 | 1.480 |
Why?
|
| Disease-Free Survival | 19 | 2025 | 865 | 1.440 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 10 | 2018 | 63 | 1.430 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2024 | 183 | 1.360 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2015 | 538 | 1.340 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2016 | 267 | 1.330 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 3 | 2021 | 8 | 1.300 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 2023 | 209 | 1.300 |
Why?
|
| Plasma Cells | 5 | 2022 | 55 | 1.260 |
Why?
|
| Bendamustine Hydrochloride | 5 | 2022 | 14 | 1.260 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2023 | 224 | 1.200 |
Why?
|
| Kaplan-Meier Estimate | 15 | 2020 | 1031 | 1.200 |
Why?
|
| Retrospective Studies | 44 | 2025 | 16242 | 1.160 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2021 | 109 | 1.140 |
Why?
|
| Smoking | 4 | 2014 | 1043 | 1.080 |
Why?
|
| Biomarkers, Tumor | 11 | 2022 | 1474 | 1.080 |
Why?
|
| Paraproteinemias | 2 | 2016 | 17 | 1.070 |
Why?
|
| Quinazolinones | 3 | 2016 | 6 | 1.050 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2016 | 195 | 1.030 |
Why?
|
| Salvage Therapy | 6 | 2019 | 194 | 1.030 |
Why?
|
| Lymphoma, Follicular | 2 | 2024 | 29 | 1.020 |
Why?
|
| Antibodies, Monoclonal | 7 | 2024 | 1018 | 1.020 |
Why?
|
| Purines | 3 | 2016 | 114 | 1.000 |
Why?
|
| Neoplasms, Second Primary | 5 | 2020 | 152 | 0.990 |
Why?
|
| Pyrazines | 5 | 2021 | 75 | 0.950 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2017 | 617 | 0.930 |
Why?
|
| Lymphocytes | 4 | 2020 | 406 | 0.900 |
Why?
|
| Signal Transduction | 12 | 2024 | 4498 | 0.900 |
Why?
|
| Anti-Retroviral Agents | 2 | 2016 | 140 | 0.880 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 4 | 2021 | 30 | 0.870 |
Why?
|
| Neutrophils | 4 | 2020 | 376 | 0.860 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2020 | 98 | 0.850 |
Why?
|
| Follow-Up Studies | 18 | 2021 | 5126 | 0.840 |
Why?
|
| Mutation, Missense | 2 | 2019 | 873 | 0.840 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2021 | 46 | 0.830 |
Why?
|
| Incidence | 13 | 2021 | 3133 | 0.800 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 504 | 0.790 |
Why?
|
| Leukemia | 4 | 2014 | 370 | 0.790 |
Why?
|
| Young Adult | 22 | 2024 | 8971 | 0.790 |
Why?
|
| Maintenance Chemotherapy | 2 | 2020 | 20 | 0.760 |
Why?
|
| Diagnosis, Differential | 7 | 2024 | 1879 | 0.750 |
Why?
|
| Walking Speed | 1 | 2021 | 11 | 0.750 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 2 | 2011 | 5 | 0.710 |
Why?
|
| Biomarkers | 15 | 2024 | 3046 | 0.710 |
Why?
|
| Neoplasm Staging | 13 | 2019 | 1233 | 0.700 |
Why?
|
| Disease Progression | 11 | 2021 | 2046 | 0.700 |
Why?
|
| Nervous System | 1 | 2021 | 127 | 0.690 |
Why?
|
| Neutropenia | 2 | 2012 | 199 | 0.690 |
Why?
|
| Risk Factors | 18 | 2021 | 10242 | 0.680 |
Why?
|
| Herpesvirus 8, Human | 3 | 2020 | 49 | 0.680 |
Why?
|
| Prospective Studies | 15 | 2023 | 6116 | 0.670 |
Why?
|
| Lymphoma, Primary Effusion | 3 | 2020 | 4 | 0.670 |
Why?
|
| Algorithms | 3 | 2017 | 1605 | 0.650 |
Why?
|
| Pleural Effusion, Malignant | 2 | 2016 | 14 | 0.640 |
Why?
|
| Immunoglobulin G | 4 | 2018 | 775 | 0.630 |
Why?
|
| Etoposide | 5 | 2024 | 114 | 0.620 |
Why?
|
| Human T-lymphotropic virus 1 | 2 | 2021 | 62 | 0.620 |
Why?
|
| Boronic Acids | 3 | 2015 | 48 | 0.620 |
Why?
|
| Blood Viscosity | 2 | 2019 | 13 | 0.610 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 1224 | 0.600 |
Why?
|
| Obesity | 3 | 2015 | 2256 | 0.590 |
Why?
|
| Stem Cell Transplantation | 6 | 2018 | 230 | 0.590 |
Why?
|
| Cohort Studies | 13 | 2021 | 4769 | 0.590 |
Why?
|
| Risk Assessment | 9 | 2024 | 3427 | 0.580 |
Why?
|
| Skin Neoplasms | 4 | 2021 | 806 | 0.580 |
Why?
|
| Withholding Treatment | 1 | 2018 | 68 | 0.570 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2018 | 141 | 0.550 |
Why?
|
| Chile | 4 | 2024 | 21 | 0.540 |
Why?
|
| von Willebrand Factor | 1 | 2018 | 196 | 0.520 |
Why?
|
| Kidney Diseases | 2 | 2021 | 480 | 0.520 |
Why?
|
| Kidney | 2 | 2021 | 1352 | 0.520 |
Why?
|
| Biopsy | 6 | 2018 | 1236 | 0.520 |
Why?
|
| Insurance Claim Review | 1 | 2016 | 27 | 0.510 |
Why?
|
| Databases, Factual | 4 | 2017 | 1172 | 0.510 |
Why?
|
| Leukemia, Plasma Cell | 3 | 2022 | 4 | 0.510 |
Why?
|
| Drug Tolerance | 1 | 2015 | 40 | 0.500 |
Why?
|
| Central Nervous System Diseases | 1 | 2016 | 105 | 0.500 |
Why?
|
| Daunorubicin | 1 | 2015 | 27 | 0.490 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 107 | 0.490 |
Why?
|
| Registries | 3 | 2020 | 1417 | 0.480 |
Why?
|
| Case-Control Studies | 10 | 2020 | 3269 | 0.480 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 43 | 0.480 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2014 | 5 | 0.480 |
Why?
|
| Dexamethasone | 4 | 2023 | 273 | 0.470 |
Why?
|
| Subcutaneous Tissue | 1 | 2014 | 15 | 0.470 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 859 | 0.470 |
Why?
|
| Acidosis, Lactic | 1 | 2015 | 30 | 0.470 |
Why?
|
| Burkitt Lymphoma | 2 | 2013 | 144 | 0.460 |
Why?
|
| Precision Medicine | 1 | 2017 | 315 | 0.460 |
Why?
|
| Clinical Trials as Topic | 6 | 2020 | 1084 | 0.460 |
Why?
|
| Eye Neoplasms | 1 | 2014 | 49 | 0.460 |
Why?
|
| Neoplasms | 4 | 2016 | 2760 | 0.460 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 284 | 0.450 |
Why?
|
| Immunoconjugates | 1 | 2014 | 37 | 0.440 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 116 | 0.420 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 1349 | 0.410 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2012 | 43 | 0.410 |
Why?
|
| Genomics | 5 | 2021 | 1484 | 0.410 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2022 | 1198 | 0.410 |
Why?
|
| Pleural Cavity | 1 | 2012 | 6 | 0.400 |
Why?
|
| Age Factors | 8 | 2018 | 2807 | 0.400 |
Why?
|
| Peritoneal Cavity | 1 | 2012 | 19 | 0.400 |
Why?
|
| Overweight | 2 | 2013 | 362 | 0.400 |
Why?
|
| United States | 12 | 2021 | 10853 | 0.400 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 188 | 0.380 |
Why?
|
| Erythrocyte Indices | 2 | 2023 | 14 | 0.380 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2011 | 2 | 0.380 |
Why?
|
| Adolescent | 13 | 2022 | 19224 | 0.370 |
Why?
|
| HIV Seronegativity | 1 | 2011 | 27 | 0.370 |
Why?
|
| Hyponatremia | 1 | 2012 | 72 | 0.370 |
Why?
|
| Immunophenotyping | 5 | 2021 | 329 | 0.370 |
Why?
|
| Latin America | 5 | 2024 | 92 | 0.370 |
Why?
|
| Lymph Nodes | 5 | 2021 | 381 | 0.350 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2024 | 718 | 0.350 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 70 | 0.350 |
Why?
|
| Mouth | 1 | 2011 | 61 | 0.350 |
Why?
|
| Lymphopenia | 1 | 2010 | 36 | 0.350 |
Why?
|
| Sarcoma, Myeloid | 1 | 2010 | 12 | 0.350 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 1206 | 0.340 |
Why?
|
| Mouth Neoplasms | 1 | 2011 | 82 | 0.340 |
Why?
|
| Primary Health Care | 1 | 2016 | 770 | 0.340 |
Why?
|
| Benzamides | 2 | 2021 | 106 | 0.340 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 219 | 0.340 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2011 | 263 | 0.340 |
Why?
|
| Population Surveillance | 4 | 2017 | 388 | 0.340 |
Why?
|
| HIV Seropositivity | 1 | 2010 | 121 | 0.330 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2021 | 1682 | 0.320 |
Why?
|
| Models, Biological | 1 | 2014 | 1454 | 0.320 |
Why?
|
| Medicare | 3 | 2020 | 423 | 0.320 |
Why?
|
| Amino Acid Substitution | 4 | 2019 | 393 | 0.320 |
Why?
|
| Erythrocyte Transfusion | 1 | 2010 | 129 | 0.320 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 660 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3543 | 0.310 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2021 | 39 | 0.310 |
Why?
|
| Lymphocyte Count | 4 | 2021 | 116 | 0.300 |
Why?
|
| Clostridium Infections | 1 | 2012 | 245 | 0.300 |
Why?
|
| beta 2-Microglobulin | 3 | 2020 | 34 | 0.300 |
Why?
|
| Logistic Models | 3 | 2020 | 1801 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 328 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-hck | 2 | 2017 | 2 | 0.280 |
Why?
|
| Remission Induction | 5 | 2014 | 299 | 0.270 |
Why?
|
| Sulfonamides | 2 | 2021 | 263 | 0.270 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 367 | 0.270 |
Why?
|
| Herpesviridae Infections | 2 | 2020 | 142 | 0.270 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 1423 | 0.260 |
Why?
|
| Fatal Outcome | 3 | 2021 | 355 | 0.260 |
Why?
|
| Age of Onset | 2 | 2018 | 585 | 0.250 |
Why?
|
| Everolimus | 2 | 2016 | 47 | 0.250 |
Why?
|
| Peru | 5 | 2021 | 47 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2021 | 172 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1134 | 0.230 |
Why?
|
| Animals | 8 | 2021 | 34000 | 0.230 |
Why?
|
| Vinblastine | 2 | 2014 | 48 | 0.230 |
Why?
|
| Medical Oncology | 2 | 2019 | 212 | 0.230 |
Why?
|
| Dacarbazine | 2 | 2014 | 83 | 0.220 |
Why?
|
| Bleomycin | 2 | 2014 | 146 | 0.220 |
Why?
|
| Bone and Bones | 2 | 2017 | 265 | 0.220 |
Why?
|
| Risk | 2 | 2016 | 754 | 0.210 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 263 | 0.210 |
Why?
|
| Point Mutation | 2 | 2021 | 345 | 0.210 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 1707 | 0.200 |
Why?
|
| Drug Resistance | 1 | 2023 | 255 | 0.200 |
Why?
|
| Edema | 1 | 2023 | 135 | 0.200 |
Why?
|
| Herpes Zoster | 1 | 2022 | 23 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1260 | 0.190 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2020 | 826 | 0.190 |
Why?
|
| Clonal Evolution | 1 | 2021 | 40 | 0.180 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 127 | 0.180 |
Why?
|
| Hospitals | 1 | 2023 | 390 | 0.180 |
Why?
|
| Boron Compounds | 1 | 2020 | 32 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1102 | 0.180 |
Why?
|
| Skin Diseases | 1 | 2022 | 124 | 0.170 |
Why?
|
| Public Health | 1 | 2022 | 262 | 0.170 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2011 | 231 | 0.170 |
Why?
|
| Syk Kinase | 1 | 2020 | 12 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 1688 | 0.170 |
Why?
|
| Paraproteins | 1 | 2020 | 2 | 0.170 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 12 | 0.170 |
Why?
|
| Boston | 2 | 2019 | 110 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2020 | 78 | 0.170 |
Why?
|
| Recurrence | 3 | 2019 | 1421 | 0.170 |
Why?
|
| Protein Multimerization | 2 | 2017 | 129 | 0.170 |
Why?
|
| Pathology, Molecular | 1 | 2020 | 58 | 0.170 |
Why?
|
| Plasmacytoma | 1 | 2019 | 7 | 0.170 |
Why?
|
| Datasets as Topic | 1 | 2020 | 89 | 0.160 |
Why?
|
| Transplantation, Autologous | 4 | 2022 | 298 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 296 | 0.160 |
Why?
|
| Pleura | 1 | 2019 | 20 | 0.160 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 788 | 0.160 |
Why?
|
| Lung | 2 | 2019 | 1476 | 0.160 |
Why?
|
| Glycine | 1 | 2020 | 168 | 0.160 |
Why?
|
| Hematology | 1 | 2019 | 37 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 142 | 0.160 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 13 | 0.160 |
Why?
|
| Propensity Score | 1 | 2020 | 215 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2018 | 36 | 0.150 |
Why?
|
| Flaviviridae Infections | 1 | 2018 | 4 | 0.150 |
Why?
|
| Flaviviridae | 1 | 2018 | 5 | 0.150 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 235 | 0.150 |
Why?
|
| Lung Injury | 1 | 2020 | 123 | 0.150 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2018 | 4 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2010 | 3057 | 0.150 |
Why?
|
| Alkylating Agents | 1 | 2017 | 11 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2022 | 2284 | 0.150 |
Why?
|
| Translocation, Genetic | 2 | 2020 | 355 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2016 | 1520 | 0.140 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 162 | 0.140 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2024 | 59 | 0.140 |
Why?
|
| Organ Specificity | 2 | 2019 | 426 | 0.140 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2017 | 21 | 0.140 |
Why?
|
| von Willebrand Diseases | 1 | 2018 | 51 | 0.140 |
Why?
|
| Plasmapheresis | 1 | 2017 | 28 | 0.140 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2017 | 540 | 0.140 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 83 | 0.140 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 373 | 0.140 |
Why?
|
| Time Factors | 5 | 2021 | 6279 | 0.140 |
Why?
|
| Syndrome | 2 | 2018 | 1116 | 0.140 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 645 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
|
| Infectious Mononucleosis | 1 | 2016 | 15 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2019 | 1252 | 0.130 |
Why?
|
| Liver Function Tests | 1 | 2016 | 100 | 0.130 |
Why?
|
| Histocytochemistry | 1 | 2016 | 99 | 0.130 |
Why?
|
| Skin | 1 | 2019 | 506 | 0.130 |
Why?
|
| Protein Binding | 2 | 2017 | 1740 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 293 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 128 | 0.130 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2016 | 31 | 0.130 |
Why?
|
| Body Surface Area | 1 | 2015 | 31 | 0.130 |
Why?
|
| Proline | 1 | 2016 | 78 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 91 | 0.130 |
Why?
|
| Sex Factors | 3 | 2017 | 1276 | 0.130 |
Why?
|
| Virus Activation | 1 | 2016 | 87 | 0.120 |
Why?
|
| Review Literature as Topic | 2 | 2013 | 44 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2016 | 122 | 0.120 |
Why?
|
| Blood-Brain Barrier | 1 | 2016 | 142 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 3146 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2016 | 133 | 0.120 |
Why?
|
| CD79 Antigens | 1 | 2015 | 1 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2018 | 332 | 0.120 |
Why?
|
| Patient Selection | 2 | 2018 | 689 | 0.120 |
Why?
|
| Castleman Disease | 1 | 2015 | 13 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 417 | 0.120 |
Why?
|
| Leukocyte Common Antigens | 1 | 2015 | 90 | 0.120 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2014 | 7 | 0.120 |
Why?
|
| Apoptosis | 3 | 2020 | 1777 | 0.120 |
Why?
|
| Leukocyte Count | 1 | 2015 | 249 | 0.120 |
Why?
|
| Leucine | 1 | 2016 | 311 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 356 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 370 | 0.120 |
Why?
|
| Genotype | 2 | 2017 | 2552 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 942 | 0.120 |
Why?
|
| Epidemiological Monitoring | 1 | 2014 | 59 | 0.120 |
Why?
|
| Databases, Bibliographic | 1 | 2014 | 19 | 0.110 |
Why?
|
| Myxoma | 1 | 2014 | 29 | 0.110 |
Why?
|
| Thalidomide | 1 | 2014 | 36 | 0.110 |
Why?
|
| HTLV-I Infections | 1 | 2014 | 6 | 0.110 |
Why?
|
| Epidemiologic Studies | 1 | 2014 | 43 | 0.110 |
Why?
|
| Unrelated Donors | 1 | 2014 | 82 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 723 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 723 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 73 | 0.110 |
Why?
|
| Codon, Nonsense | 1 | 2014 | 130 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 152 | 0.110 |
Why?
|
| Frameshift Mutation | 1 | 2014 | 180 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 142 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 611 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2014 | 116 | 0.110 |
Why?
|
| Breast Implants | 1 | 2013 | 29 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 332 | 0.110 |
Why?
|
| Rhode Island | 1 | 2013 | 5 | 0.110 |
Why?
|
| Heart Neoplasms | 1 | 2014 | 101 | 0.110 |
Why?
|
| Observational Studies as Topic | 1 | 2013 | 87 | 0.110 |
Why?
|
| Sirolimus | 1 | 2015 | 223 | 0.100 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2013 | 8 | 0.100 |
Why?
|
| Dura Mater | 1 | 2013 | 24 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 617 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 297 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2015 | 355 | 0.100 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2014 | 138 | 0.100 |
Why?
|
| Lymphocytosis | 1 | 2013 | 14 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2018 | 515 | 0.100 |
Why?
|
| Asia | 1 | 2013 | 107 | 0.100 |
Why?
|
| Splenic Neoplasms | 1 | 2012 | 11 | 0.100 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2012 | 4 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2015 | 695 | 0.100 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2012 | 6 | 0.100 |
Why?
|
| Receptors, Vasopressin | 1 | 2012 | 11 | 0.100 |
Why?
|
| Hypovolemia | 1 | 2012 | 11 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2014 | 346 | 0.100 |
Why?
|
| Hepatitis B virus | 1 | 2013 | 130 | 0.100 |
Why?
|
| Ki-1 Antigen | 1 | 2012 | 28 | 0.100 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 2496 | 0.100 |
Why?
|
| Comorbidity | 1 | 2017 | 1527 | 0.100 |
Why?
|
| Arginine Vasopressin | 1 | 2012 | 28 | 0.100 |
Why?
|
| Benzazepines | 1 | 2012 | 65 | 0.100 |
Why?
|
| Europe | 1 | 2013 | 352 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 777 | 0.100 |
Why?
|
| Hepatitis B | 1 | 2013 | 158 | 0.100 |
Why?
|
| Pericardium | 1 | 2012 | 81 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2018 | 833 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 150 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2012 | 95 | 0.090 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 73 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 544 | 0.090 |
Why?
|
| Models, Genetic | 1 | 2014 | 759 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 231 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2086 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2863 | 0.090 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2011 | 28 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2011 | 143 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2011 | 59 | 0.090 |
Why?
|
| Pesticides | 1 | 2011 | 21 | 0.090 |
Why?
|
| Exome | 1 | 2016 | 1040 | 0.090 |
Why?
|
| Sodium | 1 | 2012 | 294 | 0.090 |
Why?
|
| Vidarabine | 1 | 2011 | 80 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2016 | 746 | 0.090 |
Why?
|
| Alemtuzumab | 1 | 2011 | 88 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 186 | 0.090 |
Why?
|
| Cell Transformation, Viral | 1 | 2011 | 106 | 0.090 |
Why?
|
| Leukemic Infiltration | 1 | 2010 | 8 | 0.090 |
Why?
|
| Graves Disease | 1 | 2010 | 16 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 646 | 0.090 |
Why?
|
| Albumins | 1 | 2010 | 87 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 555 | 0.090 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 50 | 0.080 |
Why?
|
| Quality of Life | 1 | 2019 | 1898 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 251 | 0.080 |
Why?
|
| Transcriptome | 1 | 2016 | 944 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2010 | 254 | 0.080 |
Why?
|
| Thyroidectomy | 1 | 2010 | 100 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2015 | 1554 | 0.080 |
Why?
|
| Fever | 1 | 2012 | 293 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 564 | 0.080 |
Why?
|
| Viral Load | 1 | 2011 | 384 | 0.080 |
Why?
|
| Autografts | 2 | 2019 | 25 | 0.080 |
Why?
|
| Cross Infection | 1 | 2012 | 330 | 0.080 |
Why?
|
| Immunologic Factors | 2 | 2019 | 174 | 0.070 |
Why?
|
| HIV-1 | 1 | 2010 | 464 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1546 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 1589 | 0.060 |
Why?
|
| Child | 4 | 2018 | 24332 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2010 | 13983 | 0.060 |
Why?
|
| Hospitalization | 1 | 2012 | 1769 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2023 | 49 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2023 | 79 | 0.050 |
Why?
|
| Phenotype | 1 | 2013 | 4242 | 0.050 |
Why?
|
| Cell Survival | 2 | 2016 | 801 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 47 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1264 | 0.050 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2021 | 31 | 0.050 |
Why?
|
| Argentina | 1 | 2021 | 52 | 0.050 |
Why?
|
| Colombia | 1 | 2021 | 48 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 3328 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 2423 | 0.040 |
Why?
|
| Phospholipase C gamma | 1 | 2020 | 19 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 1888 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2021 | 223 | 0.040 |
Why?
|
| Serum Albumin, Human | 1 | 2019 | 7 | 0.040 |
Why?
|
| Mice | 1 | 2016 | 17581 | 0.040 |
Why?
|
| Pneumocystis carinii | 1 | 2018 | 9 | 0.040 |
Why?
|
| Portraits as Topic | 1 | 2018 | 3 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 83 | 0.040 |
Why?
|
| Technetium | 1 | 2018 | 12 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2018 | 79 | 0.040 |
Why?
|
| Exosomes | 1 | 2018 | 43 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2018 | 149 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2019 | 251 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2020 | 450 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 635 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 296 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 329 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2016 | 16 | 0.030 |
Why?
|
| London | 1 | 2016 | 12 | 0.030 |
Why?
|
| V(D)J Recombination | 1 | 2016 | 6 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2016 | 100 | 0.030 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 64 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 80 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2016 | 112 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 196 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 137 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 153 | 0.030 |
Why?
|
| Infant | 1 | 2010 | 12444 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2015 | 12 | 0.030 |
Why?
|
| Hydroa Vacciniforme | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2014 | 31 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 574 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 171 | 0.030 |
Why?
|
| Gene Expression | 1 | 2019 | 1560 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 226 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 228 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 484 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2016 | 409 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 419 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 257 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2015 | 303 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1421 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 2137 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 86 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2732 | 0.030 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 492 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2013 | 69 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 1058 | 0.030 |
Why?
|
| Family | 1 | 2016 | 561 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2016 | 1070 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1328 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1093 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 112 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1733 | 0.020 |
Why?
|
| Breast | 1 | 2013 | 216 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2016 | 777 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 222 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 1586 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 357 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2011 | 33 | 0.020 |
Why?
|
| Alleles | 1 | 2016 | 1615 | 0.020 |
Why?
|
| South America | 1 | 2011 | 39 | 0.020 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2011 | 11 | 0.020 |
Why?
|
| Graft Survival | 1 | 2013 | 532 | 0.020 |
Why?
|
| Prednisolone | 1 | 2011 | 73 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 300 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 1004 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 1746 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 1492 | 0.020 |
Why?
|
| Research Design | 1 | 2013 | 687 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 543 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 795 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 1107 | 0.020 |
Why?
|
| Calcium | 1 | 2010 | 1097 | 0.020 |
Why?
|